Results of the phase 2b part showed a significant increase in progression-free survival (PFS; primary endpoint) that was most pronounced in non-squamous NSCLC (where Muc-1 expression is expected to be the highest) and with biomarker value in the lower 3 quartiles (56). This evidence concerns the gene MUC1 and non-small cell lung carcinoma.